000			03886nam a22003615i 4500
001			289916
003			MX-SnUAN
005			20160429154728.0
007			cr nn 008mamaa
008			150903s2013 xxu| o |||| 0|eng d
020			_a9781461472919 _99781461472919
024	7		_a10.1007/9781461472919 _2doi
035			_avtls000342163
039		9	_a201509030848 _bVLOAD _c201405050239 _dVLOAD _y201402061119 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aQR355-502
100	1		_aLeGrice, Stuart. _eeditor. _9320354
245	1	0	_aHuman Immunodeficiency Virus Reverse Transcriptase : _bA Bench-to-Bedside Success / _cedited by Stuart LeGrice, Matthias Gotte.
264		1	_aNew York, NY : _bSpringer New York : _bImprint: Springer, _c2013.
300			_ax, 361 páginas 72 ilustraciones, 47 ilustraciones en color. _brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
500			_aSpringer eBooks
520			_aThe Reverse Transcriptase (RT) of Human Immunodeficiency Virus Type 1 (HIV-1) arguably ranks amongst one of the most extensively studied retroviral enzymes. Heterologous expression and purification of HIV-1 RT in the early eighties, approval of the first nucleoside analogue RT inhibitor (NRTI) in 1987, discovery of resistance to RT inhibitors, approval of the first non-nucleoside analogue RT inhibitor (NNRTI) in 1996 and the various crystal structures of RT with and without bound substrate(s) and/or inhibitors represent only a few of the important milestones that describe the a bench-to-bedside success in the continuing effort to combat HIV-1 infection and its consequences. Nucleoside and nonnucleoside RT inhibitors remain important components in frequently used drug regimens to treat the infection. RT inhibitors also play important roles in recently validated strategies to prevent transmission of the virus. The relevance of HIV-1 RT as a drug target has simultaneously triggered interest in basic research studies aimed at providing a more detailed understanding of interactions between proteins, nucleic acids, and small molecule ligands in general terms. In light of the ever-growing knowledge on structure and function of HIV-1 RT, this enzyme serves as a valuable “model system” in efforts to develop novel experimental tools and to explain biochemical processes. This monograph is designed to provide an overview of important aspects in past and current HIV-1 RT research, with focus on mechanistic aspects and translation of knowledge into drug discovery and development. The first section includes chapters with emphasis placed on the coordination of the RT-associated DNA polymerase and ribonuclease H (RNase H) activities. The second covers mechanisms of action and future perspectives associated with NRTIs and NNRTIs, while the third section includes chapters focusing on novel strategies to target the RT enzyme. Chapters of the final part are intended to discuss mechanisms involved in HIV variability and the development of drug resistance. We hope that these contributions will stimulate interest, and encourage research aimed at the development of novel RT inhibitors. The lack of bona fide RNase H inhibitors with potent antiviral activity provides an example for challenges and opportunities in the field.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700	1		_aGotte, Matthias. _eeditor. _9305475
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9781461472902
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-4614-7291-9 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c289916 _d289916